Alpha Synuclein Immunotherapy is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
[alpha-synuclein[/mechanisms/alpha-synuclein immunotherapy encompasses a class of therapeutic approaches -- both passive (monoclonal antibodies) and active (vaccines) -- designed to target and reduce pathological forms of [alpha-synuclein[/proteins/alpha-synuclein, the key protein implicated in [Parkinson's disease[/diseases/parkinsons, [Lewy body dementia[/diseases/lewy-body-dementia, [multiple system atrophy[/diseases/msa, and other [synucleinopathies[/mechanisms/synucleinopathies. The therapeutic hypothesis rests on the [prion-like spreading[/mechanisms/prion-like-spreading model of [alpha-synuclein[/proteins/alpha-synuclein pathology: misfolded [alpha-synuclein[/proteins/alpha-synuclein aggregates propagate between [neurons[/entities/neurons in a cell-to-cell manner, and antibodies that intercept extracellular [alpha-synuclein[/proteins/alpha-synuclein during this transit may slow or halt disease progression (Bhatt et al., 2024).
The most clinically advanced candidate, prasinezumab (Roche/Genentech), demonstrated signals of motor progression slowing in Phase 2 trials and advanced to Phase 3 development in 2025 -- making it the first [alpha-synuclein[/proteins/alpha-synuclein-targeting therapy to reach late-stage clinical testing. alpha-synuclein immunotherapy represents one of the most active areas of disease-modifying drug development for Parkinson's Disease (Roche, 2025).
[alpha-synuclein[/proteins/alpha-synuclein is a 140-amino acid presynaptic protein that, in its native state, plays roles in synaptic vesicle trafficking and neurotransmitter release. In synucleinopathies, [alpha-synuclein[/proteins/alpha-synuclein misfolds and aggregates into oligomers, protofibrils, and ultimately mature fibrils that form Lewy bodies and Lewy neurites -- the pathological hallmarks of PD and LBD.
The aggregation cascade follows a nucleation-dependent polymerization pathway:
A landmark discovery was that alpha spreads between connected brain regions in a stereotypical pattern described by [Braak staging[/mechanisms/braak-staging. Experimental evidence -- including the observation that embryonic dopaminergic neuron grafts develop Lewy bodies after transplantation into PD patients -- supports the prion-like cell-to-cell transmission model (Brundin et al., 2010). This extracellular phase of [alpha-synuclein[/proteins/alpha-synuclein propagation creates a therapeutic window for antibody intervention.
Different antibodies target different alpha-synuclein species:
Prasinezumab is a humanized IgG1 monoclonal antibody developed by Roche/Genentech (in collaboration with Prothena) that preferentially binds aggregated forms of alpha-synuclein. It is the most clinically advanced alpha-synuclein antibody.
Mechanism: Prasinezumab binds the C-terminal region of alpha-synuclein (epitope: residues 118-126) with higher affinity for aggregated and membrane-associated alpha-synuclein than for free monomers. Upon binding, it promotes Fc-gamma receptor-mediated microglial clearance and prevents cell-to-cell transfer of pathological alpha.
Clinical Development:
| Trial | Phase | Key Results |
|---|---|---|
| PASADENA (NCT03100149) | Phase 2 | MDS-UPDRS Part III: 35% less decline vs placebo at 52 weeks (nominal significance). No significant effect on total MDS-UPDRS. |
| PADOVA (NCT04777331) | Phase 2b | Time to confirmed motor progression: HR=0.84 [0.69-1.01], p=0.0657 (missed statistical significance but trending) |
| Phase 3 (announced 2025) | Phase 3 | Roche advancing to Phase 3 based on totality of PASADENA + PADOVA evidence |
Key Findings from PASADENA:
Key Findings from PADOVA:
Cinpanemab was a monoclonal antibody developed by Biogen targeting the N-terminal region of alpha-synuclein (residues 1-10), preferentially binding aggregated forms. In the Phase 2 SPARK trial (NCT03318523), cinpanemab showed no benefit over placebo on clinical measures (MDS-UPDRS) or DAT-SPECT imaging at 52 weeks in early PD (n=357). Development was discontinued in 2022 (Lang et al., 2022).
The failure of cinpanemab -- despite a different epitope and binding profile -- raised important questions about optimal target engagement, timing of intervention, and whether N-terminal-directed antibodies adequately intercept pathological alpha.
Lu AF82422 (amlenetug) is a humanized IgG1 antibody developed by Lundbeck targeting the C-terminal of alpha-synuclein (residues 112-117). It was engineered based on rational selection principles to maximize binding to aggregated alpha-synuclein forms relevant to disease.
Phase 1 results showed:
Phase 2 studies are evaluating lu AF82422 in PD and MSA.
MEDI1341 (bepranemab / TAK-341), developed by AstraZeneca and Takeda, was engineered with two distinctive features: enhanced brain penetration (via transferrin receptor-mediated transcytosis technology) and reduced Fc effector function (to minimize [microglial[/cell-types/microglia
UB-312 is a peptide-based active immunotherapy developed by Vaxxinity (formerly United Biomedical) designed to elicit endogenous antibody responses against pathological alpha-synuclein.
AFFITOPE vaccines, developed by Affiris, use short peptides that mimic alpha-synuclein epitopes without containing actual alpha-synuclein sequence, potentially improving safety.
ACI-7104.056, developed by AC Immune, is a next-generation active immunotherapy using a liposomal platform to target phosphorylated alpha-synuclein (pS129) -- the post-translationally modified form predominantly found in Lewy bodies. This approach aims to selectively target the most pathologically relevant alpha. Currently in preclinical/early clinical development.
A fundamental challenge for alpha-synuclein immunotherapy is achieving sufficient antibody concentrations in the brain. Typically, only ~0.1% of systemically administered IgG crosses the [blood-brain barrier[/entities/blood-brain-barrier. Strategies to address this include:
Clinical trial failures have highlighted the importance of:
Unlike [anti-amyloid antibodies] in AD where amyloid PET provides a clear pharmacodynamic readout, there is currently no established imaging biomarker for alpha-synuclein in vivo. This limits the ability to confirm target engagement and complicates trial design. Development of alpha-synuclein PET tracers is an active area of research.
The field debates which alpha are most relevant:
| Feature | Prasinezumab | Cinpanemab | Lu AF82422 | UB-312 |
|---|---|---|---|---|
| Type | Passive (mAb) | Passive (mAb) | Passive (mAb) | Active (vaccine) |
| Epitope | C-terminal (118-126) | N-terminal (1-10) | C-terminal (112-117) | Oligomer-specific |
| Preference | Aggregated > monomer | Aggregated > monomer | Aggregated > monomer | Pathological forms |
| Phase | Phase 3 (2025-) | Discontinued | Phase 2 | Phase 1+ |
| Key result | HR=0.84 motor progression | No benefit vs placebo | Target engagement confirmed | Immunogenicity confirmed |
The study of Alpha Synuclein Immunotherapy has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.